CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MaxiVAX is conducting a Phase 2 clinical trial for its cancer immunotherapy product, MaxONCO, targeting Head and Neck cancer. The trial aims to assess the safety and efficacy of the treatment compared to existing therapies.
MaxiVAX a private Swiss clinical-stage biotech company with a novel cancer immunotherapy product in development (MaxONCO) will perform Phase 2 clinical trial in Head & Neck indication and prepare the commercialization of MaxONCO, its first immuno-therapy product.
The objective of the Phase II clinical trial is to demonstrate efficacy and safety of MaxONCO in the patients treated and compare the results to the current standard of care.MaxONCO is a biological product acting as a cancer vaccine and…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
